published meta-analysis   sensitivity analysis   studies

angiotensin receptor blockers (ARBs) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias new illness compatible with Covid-19 detailed resultsMancia, 2020 0.95 [0.86; 1.05] Morales, 2020 1.10 [0.89; 1.35] 0.99[0.87; 1.13]Mancia, 2020, Morales, 2020235%moderatenot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-13 03:53 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 590,891 - roots T: 290